about
Main roads to melanomaPinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathwayAnalysis of the genome to personalize therapy for melanomaEstrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical UtilityThe antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status.Strategies and challenges in eliciting immunity to melanoma.Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapyRole of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.State of melanoma: an historic overview of a field in transition.Engineering a waste management enzyme to overcome cancer resistance to apoptosis: adding DNase1 to the anti-cancer toolbox.Molecular designing and in silico evaluation of darunavir derivatives as anticancer agents.Conditional ablation of Ikkb inhibits melanoma tumor development in mice.Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro.Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.Genotyping of cutaneous melanoma.Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cellsA phase II study of gefitinib in patients with metastatic melanoma.Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.New Perspectives of "omics" Applications in Melanoma Research.Cisplatin fails to induce puma mediated apoptosis in mucosal melanomasSNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients.Metastatic melanoma with striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanomaPathway aberrations of murine melanoma cells observed in Paired-End diTag transcriptomes.NF-κB as potential target in the treatment of melanoma.Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling.Melanoma invasion - current knowledge and future directions.Toxicogenomics of A375 human malignant melanoma cells.A novel AKT3 mutation in melanoma tumours and cell linesIssues affecting molecular staging in the management of patients with melanomaUnderstanding signaling cascades in melanomaCancer stem cells and human malignant melanomaHeterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.Wnt and related signaling pathways in melanomagenesis.Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.Small molecules and targeted therapies in distant metastatic disease.Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.CTGF is a therapeutic target for metastatic melanoma.Phosphorylated 4E-BP1 is associated with poor survival in melanoma.
P2860
Q21245465-683F6705-6CE7-4AD5-8BF4-22FDC60966E0Q21245756-47B92621-FBC0-45B9-942F-CB2E9478B175Q24601008-002538E0-FA16-4FC1-8D52-7866B8AEBCADQ28078465-71B51A16-D75F-441D-AABC-855B11496FEFQ30252521-E7FE52B4-90EE-465B-BA4A-44EA78FB6F02Q30435893-DA2F24A9-AEDD-4B4D-9111-0CBC72AF5C13Q30437344-E7217EAA-15EF-45FC-B29F-BCA5FD79DD2DQ30875021-C1403548-7FB1-4333-B799-EE085CB4E62FQ33693906-052AA7CA-0C04-4DFB-AB12-077992C15A39Q33793145-5D5EE82D-B904-45C5-87E3-213F1E936B59Q33803248-1D4C5479-F58D-41CA-AF46-035FC26FF4ADQ33968131-00BDB7E0-2AE0-4F05-B28F-5D333FD2855BQ34452761-8891DD35-DAF7-401A-8215-7A42D108BF04Q34489987-CC05E5C1-BC6B-4F09-BD83-DC0EF105BC99Q34667738-9A03DB30-FE14-454E-B93D-23312BB84487Q35043887-0017BCF4-D657-4491-9E76-B4696100FDF4Q35093992-27DE7E2D-BA53-467B-A60A-CADA920E6F81Q35581006-DFEDE283-1FA4-4C0F-9273-C826AB55B5ECQ35670683-349832CF-BD82-4925-A5A5-9080B3B1F941Q35833179-798BB14B-29FA-422E-B3EB-BD0ECD486FDFQ35839745-73DD2A2E-68D6-4F80-AFBE-D1F74EDDF8ECQ35871461-68B171CE-C527-4E95-A79A-5DA5D3787F53Q35906375-72A96DA2-BBED-4468-B644-E473FE407F4FQ35916919-0A9CADA3-8439-4726-BB1C-C4FC8962C01CQ36273561-100B54AC-89A6-4787-B1FE-72DB4288F643Q36828214-5A0B92B9-5AEA-46EE-A5DB-A742575B478EQ36918133-586E7AEB-1C02-4B88-B5DD-A7EB9226E92DQ36944047-48DD0A61-04DA-451D-9BD0-F37226E06BA1Q36990701-F36375A3-C739-4921-8C3E-1544752790F6Q37034487-7CEE93D6-E4A0-4DF6-9CB2-19D70EC7F1EDQ37114128-92148293-317F-47F8-9258-939BB1E9C526Q37152975-EE10B7D5-A2F6-48E0-9037-12769459EB3AQ37290440-9219E351-7C3E-47EA-BC56-2CB221008F99Q37328383-98D4D719-277B-45A3-8FE2-1B7B10A3A053Q37375271-B23EB805-99A2-4FA1-909B-EE91DB2209B9Q37384015-3BFA3E60-9639-427E-A4EB-ADEA7F2D3886Q37555793-DA239481-54EE-4C68-94CB-9AE68D7EFC96Q37656270-1F8F1B82-22D1-4A7F-B38C-0010A4FE1C95Q37662627-AC84194D-2DE8-4690-B026-1C41CA759BAAQ37716504-25BB1EF7-3D28-4061-A185-64A17916779E
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Genetic alterations in signaling pathways in melanoma.
@ast
Genetic alterations in signaling pathways in melanoma.
@en
type
label
Genetic alterations in signaling pathways in melanoma.
@ast
Genetic alterations in signaling pathways in melanoma.
@en
prefLabel
Genetic alterations in signaling pathways in melanoma.
@ast
Genetic alterations in signaling pathways in melanoma.
@en
P2093
P1476
Genetic alterations in signaling pathways in melanoma.
@en
P2093
Frank G Haluska
Frank S Haluska
Hensin Tsao
Vikas Goel
P304
2301s-2307s
P356
10.1158/1078-0432.CCR-05-2518
P407
P433
P577
2006-04-01T00:00:00Z